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ABSTRACT
We present here molecular dynamics simulations
and DNA conformational dynamics for a series
of trinuclear platinum [Pt3(HPTAB)]
6+-DNA adducts
[HPTAB=N,N,N’,N’,N’’,N’’-hexakis (2-pyridyl-
methyl)-1,3,5-tris(aminomethyl) benzene], including
three types of bifunctional crosslinks and four
types of trifunctional crosslinks. Our simulation
results reveal that binding of the trinuclear platinum
compound to a DNA duplex induces the duplex
unwinding in the vicinity of the platination sites,
and causes the DNA to bend toward the major
groove. As a consequence, this produces a DNA
molecule whose minor groove is more widened
and shallow compared to that of an undamaged
bare-DNA molecule. Notably, for trifunctional cross-
links, we have observed extensive DNA conforma-
tional distortions, which is rarely seen for normal
platinum–DNA adducts. Our findings, in this study,
thus provide further support for the idea that plati-
num compounds with trifunctional intra-strand or
long-range-inter-strand cross-linking modes can
generate larger DNA conformational distortions
than other types of cross-linking modes.
INTRODUCTION
Cisplatin (CP) and carboplatin are extensively used in the
treatments of many severe cancers, such as testicular,
ovarian, bladder, head and neck, cervical and non-small
cell lung cancers (1–5). However, many types of tumors
have been reported to become resistant to these platinum-
based chemotherapeutic agents (6–8). The resistance of
tumors to these compounds is primarily attributed to the
recognition and removal of Pt(II)-GG crosslinks from
DNA by proteins and enzymes through the nucleotide
excision repair (NER) pathway (9–11). For example, a
number of damage recognition proteins and cellular
proteins, especially those with high mobility group
(HMG) domains, have been shown to bind speciﬁcally
to Pt–GG intra-strand DNA adducts (12–18). Moreover,
some thiol- and selenium-containing proteins, such as
selenoenzyme thioredoxin reductase (TrxR) eﬃciently
inhibited by CP and oxaliplatin, are also major targets
for the platinum compounds within cells (19–22). To over-
come this problem, one promising approach is to design
platinum(II) complexes that can form diﬀerent types of
DNA lesions other than the typical Pt(II)–GG crosslinks
(1-4). Aliphatic polyamine-bridged polynuclear platinum
compounds represent such a novel class of platinum-based
antitumor agents. Since these complexes are capable of
forming long range intra- and inter-strand crosslinks
between Pt–drug and DNA (23,24), the DNA adducts
formed by these compounds are diﬀerent from those by
CP. Using these molecules may thus help circumvent the
CP resistance problem mentioned above. The cytotoxic
response to platinum anticancer agents is thought to be
primarily due to the formation of the intra-strand Pt–GG
adducts (6,25–29). Because proteins primarily interact
with the minor groove of DNA (30), it is hypothesized
that the ability of proteins to distinguish between
CP–GG and other cross-linking adducts probably results
from subtle diﬀerences in conformations or conforma-
tional dynamics in the Pt–DNA cross-linking modes
rather than from the physical interactions of the proteins
with the carrier ligands of the adducts in the major groove
(1,3,4,31). Therefore, gaining insights into conformational
dynamics may help better understand the cytotoxic
response to platinum drugs–DNA adducts.
Arepresentativeclassofthepolyamine-bridgedpolynuc-
lear platinum compounds which can form intra-/inter-
strand DNA adducts and display high eﬃcient antitumor
activity,hasattractedconsiderableattentioninrecentyears
(2,32–34). For instance, a well-known trinuclear platinum
compound, BBR3464, in which two monofunctional
Pt centers are bridged by linear aliphatic linkers and
the third Pt(II) one is coordinately saturated, has entered
Phase II clinical trials (35–37). These polynuclear
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platinum-based anticancer complexes, and appear to oﬀer
great potential as new anticancer agents (1,34). In addition,
a class of chelated polynuclear platinum compounds has
also been designed and exhibits interesting cytotoxicity
against human and mouse cell lines (27). More recently, a
trinuclear platinum compound [Pt3(HPTAB)Cl3]
3+
(shown in Chart 1) reported by Guo’s group, in which the
Pt(II) centers are bridged by bulky aromatic linkers, not
only shows greater stability but also produces signiﬁcantly
higher cytotoxicity than CP (38). Binding experiments of
this compound with the 18-mer duplex 50-d(GAAGAAGT
CACAAAATGT)-30 50- d(ACATTTTGTGACTTCTTC)-
30 (shown in Chart 2) suggest that the duplex oﬀers several
potential reactive sites for the Pt(II) compound to form
intra-/inter-strand bi/trifunctional crosslinks, which repre-
sent long-range DNA–Pt(II) drug adducts (39). These tri-
nuclear platinum compounds carry unique structural
properties for DNA binding and can display diﬀerent
DNA-adduct proﬁles (9,40). Long range intra- and inter-
strand cross-linking adducts between DNA and Pt(II)-
based drugs diﬀer greatly from the CP–GG adducts con-
formation-wise (2,32,41). Due to the important role of
these adducts in promoting the antitumor activity, long
range intra- and inter-strand crosslinks between DNA
and Pt(II)-based drugs have become the focal point of
interest in the studies of platinum-based anticancer drugs
(1,2,32).
Understanding the structural details of DNA bound by
thepolynuclearplatinumcompoundsmayhelpusdelineate
thefeaturesthatareresponsiblefortheremarkablepotency
of these platinum drugs (1). However, knowledge of the
precise interaction mechanisms of platinum anticancer
drugs with DNA at the molecular level is still scarce (5).
Especially, conformations and structures of Pt(II) com-
pound–DNA adducts with long range cross-linking
modes produced by trinuclear platinum compounds such
as [Pt3(HPTAB)Cl3]
3+, are not yet clear (9,40) despite the
existence of experimental data for several bifunctional
and trifunctional cross-linking modes (39). In the present
work, we used molecular dynamics simulations to study
the conformational properties of the [Pt3(HPTAB)]
6+
–DNA adducts. Seven diﬀerent adduct models with
bi/trifunctional and intra-/inter-strand crosslinks were
investigated. DNA conformational dynamics calculations
were performed to examine the diﬀerences between bifunc-
tional and trifunctional cross-linking modes and between
intra- and inter-strand cross-linking modes in these Pt(II)–
DNA adducts.
MODELS AND METHODS
Starting structures
Seven cross-linking adducts formed between the trinuclear
platinum compound, [Pt3(HPTAB)Cl3]
3+, and the 18-mer
duplex DNA, 50-d(GAAGAAGTCACAAAATGT)-30 50-
d(ACATTTTGTGACTTCTTC)-30 that was chosen from
breast/ovarian cancer-susceptibility genes BRCA1
(Genbank #U14680) (42), are presented in Chart 2, i.e.
three types of bifunctional cross-linking modes: intra-
1,4-GG crosslink I mode (assigned as 4,7-DNA), intra-
1,3-GG crosslink II mode (assigned as 26,28-DNA) and
inter-1,30-GG crosslink III mode (assigned as 7,28-DNA);
and four types of trifunctional cross-linking modes: intra-
1,2,5-AGG crosslink IV mode (assigned as 3,4,7-DNA),
intra-1,3,4-GGG crosslink V mode (assigned as 26,28,
29-DNA), intra-1,4,60-GGG crosslink VI mode (assigned
as 4,7,28-DNA) and intra-1,30,50-GGG crosslink VII
mode (assigned as 7,28,26-DNA). The connection points
of these adduct models were examined previously by dena-
turing polyacrylamide gels and MALDI–TOF MS analy-
sis (39). However, no crystal structures for these adducts
have been solved so far. From previous studies, it has been
predicted that the three Pt center atoms possibly bind to
the N7 atoms of G/A bases of DNA (43). The initial
coordinates of seven Pt(II)–DNA adducts used in our
simulations were generated by docking platinum complex
in the major groove of DNA. Since several diﬀerent orien-
tations of Pt compound coordinating with the major
groove of DNA for each binding adduct were chosen
as the starting structures for our molecular dynamics
Chart 1. X-ray structure of the trinuclear platinum compound (39).
Chart 2. The 18-mer DNA sequence and seven Pt–DNA cross-linking
modes studied in this work along with their assigned names (39).
Three types of bifunctional crosslinks: I: 4,7-DNA; II: 26,28-DNA;
III: 7,28-DNA Four types of trifunctional crosslinks: IV: 3,4,7-DNA;
V: 26,28,29-DNA; VI: 4,7,28-DNA; VII: 7,28,26-DNA.
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our MD simulations are capable of driving signiﬁcantly
distinct starting structures to a non-distinguishable one
when simulations reach equilibrium. Bump-checking was
turned on to ensure that no overlapping atoms were pro-
duced during the docking process. To compare the diﬀer-
ences between the DNA adduct conformations and an
undamaged DNA molecule, a bare-DNA (B-DNA) mol-
ecule simulation was also performed, in which an idealized
B-DNA was used as a starting structure for the simula-
tion. Given that each strand of DNA has some phosphate
groups, Na
+ counterions were added to each system to
achieve electroneutrality. The systems were explicitly sol-
vated using the TIP3P water potential inside a box large
enough to ensure the solvent shell extended to 10A ˚ in all
directions.
Force field parameter preparation
The atom types for the studied platinum compound,
except for the platinum atoms, were generated using the
ANTECHAMBER module in the AMBER9 program.
The electrostatic potentials of the platinum compound
used for RESP charge calculations were calculated at the
HF/6-31G  +LanL2DZ (44–46) level of theory using the
Gaussian03 program (47). RESP charges of the platinum
compound were derived by the RESP program based
on the calculated electrostatic potentials. The force ﬁeld
parameters of the platinum compound related to platinum
atoms were referenced from previous works (48–50).
Other force ﬁeld parameters of the platinum compound
were generated from the gaﬀ force ﬁeld in the AMBER9
program.
Molecular dynamics simulations
All MD simulations were carried out using the AMBER9
package (51) and the parm99 force ﬁeld (10,52) of
AMBER together with the parmbsc0 reﬁnement (48)
and gaﬀ (53) force ﬁeld parameters. The protocol for all
MD simulations is as follows: (1) All systems were sub-
mitted to energy minimization to remove unfavorable con-
tacts. Four cycles of minimizations were performed with
2500 steps in each minimization with harmonic restraints
ranging from 100kcalmol
 1A ˚  2, 25kcalmol
 1A ˚  2 to
10kcalmol
 1A ˚  2 on DNA and the platinum compound
positions. Finally, 5000 steps of unrestrained minimiza-
tion were carried out before the heating process. The
cutoﬀ distance used for non-bonded interactions was
10A ˚ . The SHAKE algorithm (54) was used to restrain
the bonds containing hydrogen. (2) Each energy-
minimized structure was heated over 120ps from 0 to
300K (with a temperature coupling of 0.2ps) in a constant
volume, while the positions of DNA and the platinum
compound were restrained with a small value of
10kcalmol
 1A ˚  2. (3) The unrestrained equilibration
of 200ps with constant pressure and constant tempera-
ture conditions was carried out before a trajectory
was generated for a further production simulation. The
temperature and pressure were allowed to ﬂuctuate
around 300K and 1bar respectively with a corresponding
coupling of 0.2ps. For each simulation, an integration
step of 2fs was used. (4) Production runs of 20ns were
carried out by following the same protocol. A time
point of 200ps after thermal equilibration in each simu-
lation was selected as a starting point for data
collection. During the production run, 10000 structures
from each simulation were saved for post-processing by
uniformly sampling the trajectory (5). Finally, simulated
annealing was performed for each system by allowing the
system to cool from 300 to 0K during the course of 1ns
simulation.
DNA helical parameter analysis of trajectories
The PTRAJ module of the AMBER9 program was used
to extract production conformations. These extracted
snapshots were saved in the Protein Data Bank (PDB)
format. Each nucleotide type was converted from the
AMBER format to PDB format, and the resulting snap-
shots were submitted to the CURVES program (55). The
following CURVES parameters were extracted, i.e. global
base-pair helical parameters: buckle and propeller; and
global inter base-pair step helical parameters: shift, slide,
roll and twist. Percentage occupancy distributions of the
DNA helical parameters were calculated by normalizing
the frequency distributions to 100%.
The overall bend, tilt and roll angles of DNA for the
average structures of these adducts were calculated from
the CURVES output using MadBend (http://www
.biomath.nyu.edu/index/software/Madbend/index.html)
developed by Strahs and Schlick (56). This method
evaluates the DNA curvature by summing the projected
components of local base-pair step tilt and roll angles
after adjusting the helical twist. Bends in the helical axis
deﬁned by a negative roll angle indicate bending
toward the minor groove, while bends deﬁned by a posi-
tive roll angle correspond to bending toward the major
groove (56).
RESULTS AND DISCUSSION
General characterization of the MD simulations
First, the root-mean-square deviation (RMSD) values
of all backbone atoms referenced to the corresponding
starting structures over all seven trajectories were exam-
ined to determine if each system had attained equilibrium.
It is often considered that small RMSD values of a simu-
lation indicate a stable state of a platinum–DNA (Pt–
DNA) adduct. Plots of RMSDs of seven system simula-
tions over time are shown in Figure 1. It can be seen from
Figure 1 that each Pt–DNA adduct reached equilibrium
after 1ns, and their energies were found to be stable
during the remainder of each simulation. Therefore, a
time of 1ns after thermal warm-up was selected as a start-
ing point for data analysis of each simulation. The trajec-
tory analysis for each system involves extracting the
equilibrated conformations between 1ns and 20ns of sim-
ulation time, recording 9500 snapshots at every 2ps time-
interval of each trajectory.
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conformational dynamics
Principal component analysis (PCA) a linear analysis
technique, can be used to ﬁnd the most eﬃcient represen-
tation (in the least-squares sense) of a data set in a few
dimensions (57). By calculating the eigenvectors from the
covariance matrix of a simulation and then ﬁltering the
trajectories along each of the diﬀerent eigenvectors, it is
possible to identify the dominant motions observed during
a simulation by visual inspection. A large portion of the
overall ﬂuctuations of macromolecules can often be
accounted for by a few low-frequency eigenvectors with
large eigenvalues. As PCA reduces the dimensionality of
the trajectory data, using only the ﬁrst several principal
components we can extract important dynamical features
describing collective and overall motions of the system
(58–61). To identify the dominant DNA motions in the
studied Pt–DNA adducts, PCA applied to the backbone
atoms in the seven Pt–DNA adducts results in the ﬁrst
three principal components (PC1, PC2 and PC3), which
describe about 80% of all the motion modes (Table 1).
These ﬁrst three components of conformational motions
roughly correspond to a superposition of bending,
unwinding and twisting motions.
Visual analyses of the trajectories of average DNA
structures in the simulation support the PCA dominant
motions described above. The overall centroid structures
of seven adducts from 1ns to 20ns simulations are shown
in Figure 2. It can be seen from Figure 2 that the DNA
conformation of each Pt–DNA crosslink including the
bending motion, unwinding extent and twisting degree,
shows obvious diﬀerences from the undamaged B-DNA
conformation. Especially, (i) the bending motion feature is
clearly present for all adducts; (ii) the unwinding motions
of the trifunctional cross-linking modes in the vicinity of
the platination sites lead to a large change to the DNA
groove conformation with respect to the undamaged
B-DNA molecule, which makes it more diﬃcult for
DNA repair as well as gene transcription, thus improving
the CP drug resistance; (iii) at the same time, the twisting
motions cause the DNA structures in the adducts to have
a signiﬁcant distortion from a canonical B-DNA, includ-
ing some bases moving away from the groove; (iv) the
ﬁrst three motions take place simultaneously and are
irreversible.
Hydrogen bond analysis
To estimate the stability of the DNA duplex, the occu-
pancy of all possible hydrogen bonds for each adduct
was measured by calculating the percentage of time
during the simulation that the hydrogen bonds exist.
The obtained data for the hydrogen bond occupancy are
shown in Figure 3. When compared to B-DNA, it can be
seen from Figure 3a for bifunctional crosslinks that the
hydrogen bond occupancy of base pairs in the vicinity of
the platination sites on the 50 side of the adducts shows a
signiﬁcant decrease, whereas the base pairs on the 30 side
of the adducts are almost completely intact. Apparently,
for trifunctional crosslinks, as shown in Figure 3b, distinct
diﬀerences for hydrogen bond occupancy occur in the
vicinity of the platination sites, which has hardly any
hydrogen bond occupancy for several consecutive base
pairs in these adducts, such as 5, 3 and 4bp, respectively,
for 3,4,7-DNA, 26,28,29-DNA and 7,28,26-DNA adducts.
This is a rare phenomenon for Pt–DNA adducts, which
can result in real damage to the original DNA structure.
Comparing the modes of diﬀerent types of cross-links
Figure 1. The RMSD values of all backbone atoms for (a) the simulations of B-DNA and bifunctional crosslinks and (b) the simulations of
trifunctional crosslinks with respect to the corresponding starting structures.
Table 1. Percentages of occupancy times of the ﬁrst three principal
components during the simulations of the studied Pt–DNA adducts
Adducts PC1 PC2 PC3 PCs
4,7-DNA 63.59 21.90 9.57 95.07
26,28-DNA 48.04 23.80 9.07 80.91
7,28-DNA 68.29 17.23 6.65 92.17
3,4,7-DNA 71.06 9.55 7.61 88.22
26,28,29-DNA 64.67 14.89 8.19 87.75
4,7,28-DNA 74.39 15.25 4.92 94.56
7,28,26-DNA 71.61 13.58 7.36 92.55
PCs represents sum of PC1, PC2 and PC3.
Nucleic Acids Research, 2009,Vol.37, No. 17 5933shows that the distortions of the DNA duplexes inﬂuenced
by trifunctional crosslinks are greater than those caused
by bifunctional crosslinks. Similar observations for intra-/
inter-strand cross-linking modes reveal that the distortions
of DNA conformations induced by intra-strand crosslinks
are greater than those caused by inter-strand ones.
Two types of hydrogen bonds with signiﬁcantly high
occupancy between the platinum carrier ligand and the
DNA molecule were identiﬁed and are shown in
Figure 4. One occurs between the aromatic carbon hydro-
gen atoms of the platinum compound and the oxygen/
nitrogen atoms of the bases at or near the platination
sites. The other occurs between the acyclic carbon hydro-
gen atoms of the platinum compound and the oxygen/
nitrogen atoms of the bases at or near the platination
sites. The occupancy and type of each of these hydrogen
bond combinations are summarized in Table 2. For
bifunctional crosslinks, Table 2 shows that the adducts
spend <10% of their time in conformations that allow
for the hydrogen bond formation, as shown in Figure 4a
and b for the 4,7-DNA and 7,28-DNA adducts, respec-
tively. However, the trifunctional adducts 3,4,7-DNA and
4,7,28-DNA with longer spans spend much more occu-
pancy time than the trifunctional adducts 26,28,29-DNA
and 7,28,26-DNA with shorter spans. Speciﬁcally, the
3,4,7-DNA and 4,7,28-DNA adducts spend 60% and
83% of their time in conformations that allow for the
formation of the hydrogen bonds between the compound
(a)
(d)
(b)( c)
(e)( f)( g)
Figure 2. The average centroid structures of seven adducts (the double-strand DNA backbones (green) with an arrow from 50-t o3 0-side in ribbon,
and the studied platinum compounds in stick (pink)) along with an undamaged B-DNA (light yellow). (a) 4,7-DNA, (b) 26,28-DNA, (c) 7,28-DNA,
(d) 3,4,7-DNA, (e) 26,28,29-DNA, (f) 4,7,28-DNA and (g) 7,28,26-DNA.
5934 Nucleic Acids Research, 2009, Vol. 37,No. 17carbon H atom and the N3/O2 atom of the C30/T31/T32
base, and between the compound carbon H atom and the
N7/O6 atom of the G28/A29 base, as shown in Figures 4c
and d for the 3,4,7-DNA and 4,7,28-DNA adducts,
respectively. However, the 26,28,29-DNA adduct spends
only 15.53% of its time in a conformation that allows for
the formation of the hydrogen bonds between the com-
pound carbon H atom and the N1/N3 atom of the A29
base. Thus, for the 3,4,7-DNA and 4,7,28-DNA adducts
the occupancies of hydrogen bonds are greater than those
for other adducts, suggesting that the long-range trifunc-
tional adducts make the distorted DNA conformation
more stable. These observations demonstrate that the
long-range trifunctional crosslinks form hydrogen bonds
which facilitate the DNA conformational distortion.
DNA conformational dynamics
To determine the eﬀect of the studied seven Pt–DNA
adducts on the conformational dynamics of DNA, the
frequency distributions (fraction of the time spent in
each conformation) from the trajectories of seven adducts
and an undamaged DNA simulations were calculated
using the CURVES program (55). To account for the
distortion of the whole DNA backbone by the platinum
compound, the overall bend, tilt and roll angles of the
DNA average structures for the studied adducts were cal-
culated from the CURVES output using the MadBend
program (56).
Overall helical parameters of DNA conformations. Table 3
gives the values of overall bend, tilt and roll angles for the
DNA conformations of the studied adducts. It can be seen
from Table 3 that the measured degrees of overall DNA
bend, tilt and roll angles for the bound-DNA backbone
conformation of each adduct are certainly diﬀerent from
those for the undamaged B-DNA molecule. Namely, the
average deviation percentages of helical angles with
respect to the undamaged B-DNA molecule are 134.3%
(154.6% for bend; 200.4% for tilt; 48.0% for roll) and
180.8% (199.9% for bend; 230.7% for tilt; 111.8% for
roll) for the bifunctional and trifunctional adducts, respec-
tively. As expected, the distorted degrees of bound DNA
molecules for trifunctional adducts are larger than those
for the bifunctional ones. In other words, the trifunctional
cross-linking modes can cause a greater DNA helical con-
formation distortion than the bifunctional ones, which is
consistent with previous studies (41). Interestingly, the
bend angles toward the major groove were observed for
most of the adducts studied, which suggests that there is
great stability of the bound DNA conformations for this
orientation, except for the 7,28,26-DNA adduct with the
bend angle toward the minor groove.
Base pair and base-pair step helical parameters of DNA
conformations. To address the eﬀect of diﬀerent cross-
linking modes on the DNA conformational dynamics,
the frequency distributions of the DNA helical parameters
at the base pair near the Pt–DNA connecting sites for all
types of Pt–DNA adducts including the undamaged B-
DNA were analyzed for statistical signiﬁcance by the
Kologorov–Smirnov test. Figures 5 and 6 show the distri-
butions for the bifunctional and trifunctional cross-linking
modes, respectively. The Kologorov–Smirnov test deter-
mines how signiﬁcantly these distributions diﬀer from
each other without making any assumptions regarding
the distribution of data (non-parametric and distribu-
tion-free). The DNA helical parameters include the base-
pair helical parameters of propeller and buckle, and the
base-pair step helical parameters of shift, slide, roll and
twist. Those helical parameters can be used to measure the
extent of a DNA structure deviation from its canonical
reference state. As expected, the positions with all param-
eter changes fall in the vicinity of the platination sites.
Cases in which the frequency distributions of the DNA
helical parameters were signiﬁcantly diﬀerent from the
undamaged B-DNA for three types of the bifunctional
cross-linking Pt–DNA adducts are shown in Figure 5.
To compare the three bifunctional adducts to the
undamaged B-DNA, there were several distinct diﬀerences
identiﬁed. Namely, the diﬀerences include (1) for the
4,7-DNA adduct, the propeller twist/buckle for the
G4 C33 and G7 C30 base pairs, shift/slide/roll/twist for
Figure 3. Hydrogen bond occupancies of base pairs along with base-
pair steps for each adduct: (a) for 4,7-DNA (square), 26,28-DNA
(down-triangle), 7,28-DNA (circle); (b) 3,4,7-DNA (square), 26,28,
29-DNA (circle), 4,7,28-DNA (up-triangle) and 7,28,26-DNA (down-
triangle).
Nucleic Acids Research, 2009,Vol.37, No. 17 5935the G4 A5 base-pair step, and shift/twist for the G7 T8
base-pair step; (2) for the 26,28-DNA adduct, the propel-
ler twist for the C9 G28 base pair, buckle for the C11 G26
base pair, shift/slide/roll/twist for the G26 T27 base-pair
step, and shift/twist for the G28 A29 base-pair step; (3) for
the 7,28-DNA adduct, buckle for the C9 G28 base pair,
shift/twist for the G7 T8/G28 A29 base-pair step. These
diﬀerences indicate that the conformational dynamics
proﬁle of B-DNA is altered by the platinum adducts.
Especially, the proﬁles of frequency distributions of the
base-pair helical and base-pair step parameters for the
4,7-DNA adduct show extensively ﬂat curves far from
the location of the undamaged B-DNA, which implies
that the long span of platinum adducts allows for
the large conformational ﬂexibility of DNA backbones.
In addition, for the intra-strand 4,7-DNA and
(a)
(d)
(b)
(c)
Figure 4. Hydrogen bonds between platinum ligands and DNA: the bases in DNA and the platinum compound in tube, carbon atoms in gray,
nitrogen atoms in blue, oxygen atoms in red and hydrogen atoms in white; (a) 4,7-DNA, (b) 26,28-DNA, (c) 3,4,7-DNA and (d) 4,7,28-DNA.
Table 2. Occupancies of hydrogen bonds between carbon hydrogen
atoms of the platinum compound (electron acceptor) and near bases
on the DNA (electron donor)
Adducts Electron donor Electron acceptor Occupancy (%)
4,7-DNA G4/O6 H-Cc
a 8.60
A5/N7 H-Ca
b 5.95
T32/O2 H-Ca
b 1.28
26,28-DNA A29/N7 H-Ca
b 8.53
7,28-DNA T8/N3 H-Ca
b 4.45
3,4,7-DNA T32/O2 H-Ca
b 60.60
T31/N3 H-Cc
a 38.43
T8/O2 H-Ca
b 25.84
C30/N3 H-Ca
b 17.73
C30/O2 H-Ca
b 5.26
26,28,29-DNA G28/O6 H-Ca
b 15.53
A29/N3 H-Ca
b 9.12
A29/N1 H-Ca
b 7.67
4,7,28-DNA G28/O6 H-Cc
b 83.79
A29/N7 H-Ca
b 51.96
7,28,26-DNA T25/O4 H-Ca
b 2.63
Cc
a: acyclic carbon atom in the linker region; Ca
b: aromatic carbon
atom in the pyridyl group.
Table 3. Values of average overall bend, tilt and roll angles (8) for the
DNA conformations of the studied adducts and undamaged B-DNA
Adducts Bend Tilt Roll
B-DNA 21.8 10.3 18.4
4,7-DNA 52.1 42.2 26.7
26,28-DNA 57.2 56.5 6.8
7,28-DNA 43.9 39.2 11.8
3,4,7-DNA 77.4 59.2 46.7
26,28,29-DNA 39.9 5.1 41.2
4,7,28-DNA 72.7 62.4 35.7
7,28,26-DNA 71.6 55.3  32.3
5936 Nucleic Acids Research, 2009, Vol. 37,No. 17Figure 5. Selected frequency distributions of the representative DNA duplex helical parameters for the central binding base pairs for the bifunctional
crosslinks.
Nucleic Acids Research, 2009,Vol.37, No. 17 5937Figure 6. Selected frequency distributions of the representative DNA duplex helical parameters for the central binding base pairs for the trifunctional
crosslinks.
5938 Nucleic Acids Research, 2009, Vol. 37,No. 1726,28-DNA adducts, the diﬀerences between their DNA
helical parameters and those of an undamaged B-DNA
are more striking than those for the inter-strand
7,28-DNA adduct, which agrees with previous studies
(62–64).
The frequency distributions of DNA helical parameters
for four types of the trifunctional cross-linking Pt–DNA
adducts are shown in Figure 6 along with the distribution
patterns of the undamaged B-DNA. Between the four tri-
functional Pt–DNA adducts and the undamaged B-DNA,
there are still several distinct diﬀerences identiﬁed.
Namely, the diﬀerences include (i) for the 3,4,7-DNA
adduct, the propeller twist/buckle for the A3 T34,
G4 C33 and G7 C30 base pairs, shift/slide/roll/twist for
the G4 A5 base-pair step, and roll for the G7 T8 base-
pair step; (ii) for the 26,28,29-DNA adduct, the propeller
twist/buckle for the C9 G28 base pair, buckle for the
C11 G26 base pair, shift/roll/twist for the G26 T27 base-
pair step, and twist for the G28 A29 base-pair step; (iii) for
the 4,7,28-DNA adduct, the propeller twist for the G4 C33
base pair, buckle for the G7 C30 base pair, shift/roll/twist
for the G4 A5 base-pair step, slide/roll/twist for the G7 T8
base-pair step, and twist for the G28 A29 base-pair step;
(iv) for the 7,28,26-DNA adduct, propeller twist/buckle
for the C9 G28 base pair, buckle for the G7 C30/
C11 G26 base pairs, shift/roll/twist for the G26 T27
base-pair step and twist for the G28 A29 base-pair step.
Of note, the long-range trifunctional modes of the
1,5-intra-strand 3,4,7-DNA and 1,60-inter-strand 4,7,28-
DNA adducts show more signiﬁcant diﬀerences in the
frequency distributions of the DNA helical parameters
from the undamaged B-DNA than the other two adducts,
which is consistent with previous studies (62–66).
Next, to compare the bifunctional to trifunctional cross-
link modes, it is obvious from the frequency distributions
of the DNA helical parameters that the distortions of
DNA conformations induced by the trifunctional cross-
link modes are larger than those caused by the bifunc-
tional ones, such as the 4,7-DNA versus the 3,4,7-DNA
adduct, and the 7,28-DNA versus the 7,28,26-DNA one.
When comparing the 4,7-DNA adduct to 3,4,7-DNA
adduct, there are some noticeable diﬀerences. For the
base-pair helical parameters, the diﬀerences were observed
for the propeller twist/buckle at the G4 C33 and G7 C30
base pairs of both the 4,7-DNA and 3,4,7-DNA adducts.
However, extra diﬀerence was also observed for the
propeller twist/buckle at the A3 T34 base pair of the
3,4,7-DNA adduct. Such diﬀerence suggests that the tri-
functional mode in the 3,4,7-DNA adduct can induce a
distortion in the DNA conformation more eﬃciently than
the bifunctional mode in the 4,7-DNA adduct. Similar
observations can been made for other bifunctional
7,28-DNA and trifunctional 7,28,26-DNA adducts when
comparing them with each other. These results support
previous experimental and computational studies (1,2,41).
Correlation between platinum ligand hydrogen bond
formation and DNA conformational dynamics
Because the formation of hydrogen bonds can inﬂuence
the conformational dynamics of Pt–DNA adducts (41),
a large number of examples in which the frequency distri-
bution of DNA helical parameters is associated with the
pattern of hydrogen bond formation suggests that the
conformational dynamics of many DNA helical para-
meters in the vicinity of the platination sites is strongly
correlated with the pattern of hydrogen bond formation.
For most of the DNA helical parameters shown, there is a
clear diﬀerence in the distribution of the DNA helical
parameters when the hydrogen bond exists at the base
pairs. In the case of the 3,4,7-DNA adduct, the hydrogen
bond patterns are formed (60%) at the bases C30, T31 and
T32 (shown in Table 2). The frequency distributions of the
DNA helical parameters associated with these hydrogen
bonds are generally either almost identical (G7 C30 pro-
peller twist/buckle) or very similar (G4 C33 propeller
twist/buckle, G4 A5 shift/slide, G7 T8 roll). A similar
observation for the 4,7,28-DNA adduct can also be seen
in this work. These data suggest that the DNA conforma-
tions in which the hydrogen bonds are seen in the vicinity
of the platination sites may represent conformational tran-
sitions. However, these patterns are not universal. For the
26,28,29-DNA adduct, there appear to be clear diﬀerences
in the distributions of the DNA helical parameters from
those of an undamaged B-DNA whose hydrogen bonds
(15.53%) exist at only one base.
Groove parameters and dimensions for the
Pt–DNA adducts
Based on previous experimental observations on the
eﬀects of platinum drugs causing the minor groove of
DNA to become widened and shallowed (39), Figure 7
compares the minor groove widths and depths from the
time-averaged structures of the trifunctional Pt–DNA
adducts using an undamaged B-DNA of the same length
and sequence as a reference. An undamaged and canonical
B-DNA has an average minor groove width of 5.87A ˚ and
a depth of 4.64A ˚ (67). It is obvious from Figure 7a and b
that the minor groove widths and depths change signiﬁ-
cantly at or near the vicinity of the platination sites with
respect to the undamaged B-DNA. Especially, as the
minor groove increases its width, the corresponding
depths become shallow as compared to those from a
normal B-DNA. For instance, the minor groove widths
of the 3,4,7-DNA and 26,28,29-DNA adducts are widened
by 106% (from 5.87 to 12.1A ˚ ) and by 128% (from 5.87 to
13.4A ˚ ) at the G7 C30 and C11 G26 base pairs, respec-
tively (as shown in Figure 7a). Their corresponding
minor groove depths are shoaled by 57% (from 4.64 to
2.0A ˚ ) and by 81% (from 4.64 to 0.9A ˚ ), respectively,
compared to a normal B-DNA (as shown in Figure 7b).
As expected, Figure 7c presents the properties of the
widened minor groove width versus the shallow minor
groove depth for the 26,28,29-DNA adduct.
Visual analyses of the conformation details at some
base pairs of the 26,28,29-DNA adducts and of an unda-
maged B-DNA support above observations (as shown in
Figure 8). In fact, the rigid linker of the trinuclear plati-
num compound makes it very diﬃcult to span over more
than four base pairs unless the DNA molecule has been
greatly distorted. It is clearly seen from Figure 8a that the
Nucleic Acids Research, 2009,Vol.37, No. 17 5939minor groove width at the C11 G26 base pair is much
wider than that of the undamaged B-DNA. Accordingly,
the minor groove depth at the C11 G26 base pair
shown in Figures 8b is greatly shoaled with respect to
the undamaged B-DNA. In addition, it is also noticeable
from Figure 8a that the adjacent bases of C9 and A10
near the platination sites have frayed from the groove of
DNA and thus cause a large distortion in the DNA
conformation. However, the corresponding trajectories
reveal that such distorted conformations of those trifunc-
tional crosslink adducts are quite stable during the simu-
lations, which might suggest that such conformational
conversion is feasible and irreversible. These observations
demonstrate the fact that the trifunctional intra-strand/
long-span-inter-strand crosslinks induce more extensive
DNA conformation damage than other types of crosslinks
(24,68).
CONCLUSIONS
Molecular dynamics simulations and DNA dynamics
analyses for a series of the trinuclear Pt–DNA adducts,
including three types of the bifunctional crosslinks
and four types of the trifunctional crosslinks, were
carried out to examine the distortions inﬂicted on the
DNA double-helical structure. In both bi- and trifunc-
tional crosslinks, the extent of DNA conformational
distortions induced by intra-strand crosslinks is greater
than that caused by inter-strand crosslinks with the
same span. For intra- and inter-strand crosslinks, the
long-range crosslinks in Pt–DNA adducts can signiﬁcantly
facilitate DNA conformational distortion. Moreover, by
inducing the DNA duplex unwinding in the vicinity of
the platination sites and causing it to bend toward the
major groove, the trifunctional crosslinks of the studied
Pt–DNA adducts can produce a widened and shallow
minor groove, which is a rare phenomenon for normal
platinum–DNA adducts. The durable stabilities of these
distorted DNA conformations on a nanosecond time scale
can be advantageous in improving the antitumor activity
and reducing the resistance of tumors to platinum drugs
(4). Our simulation results provide useful insights for a
better understanding of how a DNA conformation is
aﬀected by a platinum drug in atomic detail, and may
aid in the design of other platinum-based DNA-binding
agents.
Figure 7. Minor groove widths and depths for the time-averaged struc-
tures of the DNA conformations in the four types of the trifunctional
crosslinks: (a) and (b): B-DNA (red line with diamond), 3,4,7-DNA
(black line with square), 26,28,29-DNA (magenta line with circle),
4,7,28-DNA (blue line with up-triangle), and 7,28,26-DNA (green line
with circle); (c): the minor groove parameters of DNA in the 26,28,29-
DNA adduct (magenta line with circle for width and light-orange line
with diamond for depth).
Figure 8. Conformation details of DNA base pairs in the 26,28,
29-DNA adduct along with the corresponding undamaged B-DNA
base pairs: double-strand DNA backbone with light blue and the
undamaged B-DNA with light yellow. (a) Front view of DNA back-
bone for 8–11bp; (b) side view of DNA backbone.
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